The Effects of Retrogression and Reaging on Aluminum Alloy 2099 (C458)

The objective of this study was to investigate the feasibility of performing retrogression and reaging (RRA) heat treatments on 2099 aluminum-lithium alloy. The retrogression temperatures were 200-250 A degrees C and retrogression times were 5-60 min. Half of the samples were exposed to a salt fog environment. Interestingly, the samples exposed to salt spray had consistently higher mechanical tensile properties than those which were not exposed

The Effects of Retrogression and Reaging on Aluminum Alloy 2195

A retrogression and reaging (RRA) treatment was performed on 2195 Al-Li Alloy. The exposure times were from 5 to 60 min, and the temperatures were from 200 to 250 A degrees C. Samples that were exposed to a salt spray test had overall similar mechanical properties as compared to those that were not exposed. The percent elongation, however, was significantly deteriorated due to the salt spray exposure. The mechanical properties of the 2195 samples were compared to those of 2099 samples exposed to similar treatments in an earlier study

Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

Background: Semaglutide, a GLP-1 receptor agonist, reduces the risk of major adverse cardiovascular events (MACE) in people with overweight or obesity, but the effects of this drug on outcomes in patients with atherosclerotic cardiovascular disease and heart failure are unknown. We report a prespecified analysis of the effect of once-weekly subcutaneous semaglutide 2·4 mg on ischaemic and heart failure cardiovascular outcomes. We aimed to investigate if semaglutide was beneficial in patients with atherosclerotic cardiovascular disease with a history of heart failure compared with placebo; if there was a difference in outcome in patients designated as having heart failure with preserved ejection fraction compared with heart failure with reduced ejection fraction; and if the efficacy and safety of semaglutide in patients with heart failure was related to baseline characteristics or subtype of heart failure. Methods: The SELECT trial was a randomised, double-blind, multicentre, placebo-controlled, event-driven phase 3 trial in 41 countries. Adults aged 45 years and older, with a BMI of 27 kg/m2 or greater and established cardiovascular disease were eligible for the study. Patients were randomly assigned (1:1) with a block size of four using an interactive web response system in a double-blind manner to escalating doses of once-weekly subcutaneous semaglutide over 16 weeks to a target dose of 2·4 mg, or placebo. In a prespecified analysis, we examined the effect of semaglutide compared with placebo in patients with and without a history of heart failure at enrolment, subclassified as heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, or unclassified heart failure. Endpoints comprised MACE (a composite of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death); a composite heart failure outcome (cardiovascular death or hospitalisation or urgent hospital visit for heart failure); cardiovascular death; and all-cause death. The study is registered with ClinicalTrials.gov, NCT03574597. Findings: Between Oct 31, 2018, and March 31, 2021, 17 604 patients with a mean age of 61·6 years (SD 8·9) and a mean BMI of 33·4 kg/m2 (5·0) were randomly assigned to receive semaglutide (8803 [50·0%] patients) or placebo (8801 [50·0%] patients). 4286 (24·3%) of 17 604 patients had a history of investigator-defined heart failure at enrolment: 2273 (53·0%) of 4286 patients had heart failure with preserved ejection fraction, 1347 (31·4%) had heart failure with reduced ejection fraction, and 666 (15·5%) had unclassified heart failure. Baseline characteristics were similar between patients with and without heart failure. Patients with heart failure had a higher incidence of clinical events. Semaglutide improved all outcome measures in patients with heart failure at random assignment compared with those without heart failure (hazard ratio [HR] 0·72, 95% CI 0·60-0·87 for MACE; 0·79, 0·64-0·98 for the heart failure composite endpoint; 0·76, 0·59-0·97 for cardiovascular death; and 0·81, 0·66-1·00 for all-cause death; all pinteraction>0·19). Treatment with semaglutide resulted in improved outcomes in both the heart failure with reduced ejection fraction (HR 0·65, 95% CI 0·49-0·87 for MACE; 0·79, 0·58-1·08 for the composite heart failure endpoint) and heart failure with preserved ejection fraction groups (0·69, 0·51-0·91 for MACE; 0·75, 0·52-1·07 for the composite heart failure endpoint), although patients with heart failure with reduced ejection fraction had higher absolute event rates than those with heart failure with preserved ejection fraction. For MACE and the heart failure composite, there were no significant differences in benefits across baseline age, sex, BMI, New York Heart Association status, and diuretic use. Serious adverse events were less frequent with semaglutide versus placebo, regardless of heart failure subtype. Interpretation: In patients with atherosclerotic cardiovascular diease and overweight or obesity, treatment with semaglutide 2·4 mg reduced MACE and composite heart failure endpoints compared with placebo in those with and without clinical heart failure, regardless of heart failure subtype. Our findings could facilitate prescribing and result in improved clinical outcomes for this patient group. Funding: Novo Nordisk

Early Projection in CLP(R)

. During the evaluation of a constraint logic program, many local variables become inaccessible, or dead . In Prolog and other programming languages, the data bound to local variables can be removed automatically by garbage collection. The case of CLP is more complex, as the variables may be involved in several constraints. We can consider dead variables to be existentially quantified. Removing an existential variable from a set of constraints is then a problem of quantifier elimination, or projection. Eliminating variables not only allows recovery of space but also can decrease the cost of further consistency tests. Surprisingly, the existing systems do not exploit these advantages. Instead, the primary use of projection is as a mechanism for obtaining answer constraints. In this paper, we will give a general system architecture for automatic early projection and specify the heuristics for CLP(R) together with an in-situ removal method. We then show the effectiveness of early projecti..

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

BACKGROUN